scholarly journals WW domain binding protein 5 induces multidrug resistance of small cell lung cancer under the regulation of miR-335 through the Hippo pathway

2016 ◽  
Vol 115 (2) ◽  
pp. 243-251 ◽  
Author(s):  
Ruixiang Tang ◽  
Yingying Lei ◽  
Bingshuang Hu ◽  
Jie Yang ◽  
Shun Fang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Multidrug Resistance ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Binding Protein ◽  
Hippo Pathway ◽  
Small Cell ◽  
Small Cell Lung ◽  
Ww Domain ◽  
The Hippo Pathway

scholarly journals Evaluation of Hippo Pathway and CD133 in Radiation Resistance in Small-Cell Lung Cancer

2021 ◽  
Vol 2021 ◽  
pp. 1-8
Author(s):  
Kui Yang ◽  
Yang Zhao ◽  
Yonghao Du ◽  
Ruixiang Tang
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Radiation Resistance ◽  
Hippo Pathway ◽  
Small Cell ◽  
Cell Counting ◽  
Disease Stage ◽  
Small Cell Lung ◽  
The Hippo Pathway

Although the Hippo pathway and CD133 have been reported to play pertinent roles in a variety of cancer, knowledge about their contribution to radiation resistance in small-cell lung cancer (SCLC) is limited. In this first-of-a-kind study, we have reported the expression of key Hippo pathway proteins in SCLC patients by immunohistochemical staining. We assessed the involvement of yes-associated protein 1 (YAP1) in radiation resistance by Cell Counting Kit-8 (CCK-8) and flow cytometry. In addition, we analysed the impact of CD133 on radiotherapy for SCLC. The mammalian Ste20-like serine/threonine kinase 2(MST2), pMST2, and pYAP1 in the Hippo pathway were not significantly associated with the disease stage and survival time in patients with SCLC. However, the pYAP1 expression showed some significance in the “YAP/TAZ subgroup” of SCLC patients. The proportion of CD133 in the SCLC cells was controlled by the YAP1 expression. The CD133 and YAP1 levels were significantly correlation with each other in tissues of SCLC patients. We sorted and isolated the CD133+ and CD133−cells in H69 and found that the cell surface glycoprotein may be associated with the radiation resistance of SCLC.In summary, we have firstly reported the expression of key Hippo pathway proteins in SCLC patients. Furthermore, we also identified that CD133 may be controlled by the expression of YAP1 in the Hippo pathway and that CD133 may be associated with the radiation resistance of SCLC.

Knockdown of SIPA1L3 Inhibits the Proliferation and Invasion of Non–Small Cell Lung Cancer Cells Through the Hippo Pathway

2021 ◽  
Author(s):  
Si Wang ◽  
Qiang Han ◽  
Xue-Zhu Rong ◽  
Ming-Fang Sun ◽  
Ke-Xin Diao ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Cells ◽  
Cell Lung Cancer ◽  
Hippo Pathway ◽  
Small Cell ◽  
Lung Cancer Cells ◽  
Small Cell Lung ◽  
Core Proteins ◽  
The Hippo Pathway

Abstract Background: SIPA1L3 is a member of the signal-induced proliferation-associated (SIPA) protein family, only limited data about the SIPA1L3 are currently available in human carcinoma. Our present study provides the expression pattern and function of SIPA1L3 in non-small cell lung cancer (NSCLC).Methods: We performed immunohistochemistry to detect the distribution of SIPA1L3 in NSCLC specimens and analyzed the relationship between SIPA1L3 expression and patients clinicopathological feature. We used small interfering RNA (siRNA) to specifically silence SIPA1L3, then investigated its effect on cell growth and invasion in human lung cancer cell lines. Western blot and immunoprecipitation were performed to show the interaction of SIPA1L3 with the core proteins of Hippo pathway, and the Hippo pathway activity.Results: Immunohistochemical staining showed that SIPA1L3 was cytoplasmic increasing in 147 of 217 cases. High levels of SIPA1L3 expression were associated with poor differentiation and a high tumor node metastasis stage, positive lymph nodal status, and poor prognosis. Downregulation of SIPA1L3 inhibited cell EMT, growth, and invasion. As well as SIPA1L3 inhibited Hippo pathway. SIPA1L3 interacted with AMOT, which inhibited AMOT binding to Pals, then decreased nuclear location of YAP.Conclusions: SIPA1L3 overexpression may be a marker for advanced NSCLC. SIPA1L3 reduction inhibits the proliferative and invasive ability of the lung cancer cells, which involves the Hippo pathway by contacting with AMOT.

735 Multidrug Resistance Transporter Pgp as a Pathogenetic Factor of Non-small Cell Lung Cancer

2012 ◽  
Vol 48 ◽  
pp. S175
Author(s):  
T.A. Bogush ◽  
E.A. Dudko ◽  
M.V. Tikchomirov ◽  
A.B. Ravcheeva ◽  
B.E. Polotsky ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Multidrug Resistance ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Pathogenetic Factor ◽  
Multidrug Resistance Transporter

scholarly journals CUG ‐binding protein 1 ( CUGBP 1) expression and prognosis of brain metastases from non‐small cell lung cancer

2015 ◽  
Vol 7 (1) ◽  
pp. 32-38 ◽  
Author(s):  
Xiaofei Wang ◽  
Wenjie Jiao ◽  
Yandong Zhao ◽  
Liangdong Zhang ◽  
Ruyong Yao ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Brain Metastases ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Binding Protein ◽  
Small Cell ◽  
Small Cell Lung

scholarly journals YAP1 promotes multidrug resistance of small cell lung cancer by CD74‐related signaling pathways

2019 ◽  
Vol 9 (1) ◽  
pp. 259-268 ◽  
Author(s):  
Yongchun Song ◽  
Yanqin Sun ◽  
Yingying Lei ◽  
Kui Yang ◽  
Ruixiang Tang
Keyword(s):  
Lung Cancer ◽  
Multidrug Resistance ◽  
Small Cell Lung Cancer ◽  
Signaling Pathways ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung
Sign in / Sign up

Export Citation Format

Share Document